Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
173. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G,<br />
Alligood KJ, Spector NL 2002 Anti-tumor activity of GW572016: a dual<br />
tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream<br />
Erk1/2 and AKT pathways. Oncogene 21:6255-63<br />
174. Blackwell K, Kaplan EH, Franco SX, Marcom PK, Maleski JE, Sorensen<br />
MJ, Berger MS 2004 A phase II, open label, multicenter study of GW572016 in<br />
patients with trastuzumab-refractory metastatic breast cancer. Proceeding of the<br />
American Society of Clinical Oncology. 22:3006<br />
175. Burris HA, 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B,<br />
Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch<br />
KM, Stead A, Mangum S, Spector NL 2005 Phase I safety, pharmacokinetics,<br />
and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of<br />
epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients<br />
with metastatic carcinomas. J Clin Oncol 23:5305-13<br />
176. Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N,<br />
Mann G, Tao Y, Ellis MJ 2006 The combination of letrozole and trastuzumab as<br />
first or second-line biological therapy produces durable responses in a subset of<br />
H<strong>ER</strong>2 positive and <strong>ER</strong> positive advanced breast cancers. Breast Cancer Res Treat<br />
102(1):43-9<br />
177. Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A,<br />
Tjulandin S, Jahn M, Lehle M, Jones A Trastuzumab prolongs progression-free<br />
survival in hormone-dependent and H<strong>ER</strong>2-positive metastatic breast cancer. San<br />
68